000			02157 a2200553 4500
005			20250517040234.0
264		0	_c20151104
008			201511s 0 0 eng d
022			_a1530-0293
024	7		_a10.1097/CCM.0000000000001132 _2doi
040			_aNLM _beng _cNLM
100	1		_aChristie, Jason D
245	0	0	_aA Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome. _h[electronic resource]
260			_bCritical care medicine _cSep 2015
300			_a1859-69 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aC-Reactive Protein _xdrug effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aHospital Mortality
650	0	4	_aHumans
650	0	4	_aInflammation Mediators _xmetabolism
650	0	4	_aInterleukin-6 _xbiosynthesis
650	0	4	_aInterleukin-8 _xdrug effects
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPyridones _xadministration & dosage
650	0	4	_aPyrimidines _xadministration & dosage
650	0	4	_aReceptors, Tumor Necrosis Factor, Type I _xdrug effects
650	0	4	_aRespiratory Distress Syndrome _xprevention & control
650	0	4	_aTrauma Severity Indices
650	0	4	_aWounds and Injuries _xdrug therapy
650	0	4	_ap38 Mitogen-Activated Protein Kinases _xantagonists & inhibitors
700	1		_aVaslef, Steven
700	1		_aChang, Philip K
700	1		_aMay, Addison K
700	1		_aGunn, Scott R
700	1		_aYang, Shuying
700	1		_aHardes, Kelly
700	1		_aKahl, Lesley
700	1		_aPowley, William M
700	1		_aLipson, David A
700	1		_aBayliffe, Andrew I
700	1		_aLazaar, Aili L
773	0		_tCritical care medicine _gvol. 43 _gno. 9 _gp. 1859-69
856	4	0	_uhttps://doi.org/10.1097/CCM.0000000000001132 _zAvailable from publisher's website
999			_c25008888 _d25008888